Passage Bio Stock Plunges as FDA Demands Full Randomized Trial for PBFT02
Passage Bio fell after the FDA demanded a larger trial; the drug shows promise for brain disease, but its future is now costlier and slower.
/ 190 items
#XY Event-Driven Stocks↓
Perspective Therapeutics Shares Positive 2026 Trial Update – 43% Response Rate in Advanced Neuroendocrine Tumors
New alpha therapy for advanced NETs shows good safety and early tumor shrinkage in ~43% patients, with encouraging results so far.
Kura Oncology Stock Surges as Darlifarib + Cabozantinib Shows Strong Results in Tough Kidney Cancer Cases
Kura Oncology’s combo drug shrank kidney tumors in early trial, controlled cancer in most patients, stock jumped.
AxoGen Stock Jumps as Cigna Adds Coverage for Avance Nerve Graft in Breast Reconstruction
AxoGen shares rose after Cigna will cover its nerve graft from Apr 2026, helping more patients get nerve repair after surgery.
MeiraGTx Stock Drops After $100M Share Offering and Bota-Vec Buy from Johnson & Johnson
MeiraGTx stock fell after $100M share sale to raise cash. Money will fund gene therapy drugs and future launches.
Achieve Life Sciences Stock Jumps as New CEO and $354 Million Funding Fuel Launch of First New Quit-Smoking Pill in 20 Years
Achieve Life Sciences jumps after CEO change, funding news, and progress on smoking/vaping quit drug cytisinicline.